Margrit Marti

Margrit Marti’s practice focuses on mergers & acquisitions, private equity and venture capital. She also advises clients on IPOs and other equity capital markets transactions as well as in matters of corporate law, securities regulation and corporate governance.

• Advised Windward Bio on its USD 200 m Series A financing;
• Advised EQT on its sale of 10% in Galderma to L’Oréal;
• Advised Galderma on its IPO on SIX Swiss Exchange;
• Advised VectivBio (Nasdaq: VECT) with respect to the public cash tender offer from Ironwood Pharmaceuticals (USD 1 bn), and previously on VectivBio’s follow-on public offerings and concurrent private placement and its IPO on Nasdaq;
• Advised AMF Medical and its shareholders on the USD 200 m sale to Tandem Diabetes Care;

• Capital markets: Equity
• M&A
• Private equity

• Consumer goods and services
• Financial services
• Healthcare
• Pharmaceutical and life sciences
• Technology and telecommunications

• LL.M., Certificate in Business Law, University of California, Berkeley, 2015

• M.A. HSG in Law, University of St. Gallen, 2009

• Swiss Bar Association 
• Zurich Bar Association
• International Bar Association

• Switzerland Bar Association, 2011